tecnazene has been researched along with Batten Turner Congenital Myopathy in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gardberg, M; Hackman, P; Jokela, M; Kiiski, K; Lehtokari, VL; Pelin, K; Sagath, L; Udd, B; Välipakka, S; Vihola, A; Wallgren-Pettersson, C | 1 |
| Kim, DS; Kim, HS; Lee, CH; Park, YE; Shin, JH | 1 |
2 other study(ies) available for tecnazene and Batten Turner Congenital Myopathy
| Article | Year |
|---|---|
Congenital asymmetric distal myopathy with hemifacial weakness caused by a heterozygous large de novo mosaic deletion in nebulin.
Topics: Adult; Biopsy; Distal Myopathies; Exons; Facial Muscles; Female; Finland; Heterozygote; Humans; Mosaicism; Muscle Proteins; Muscle Weakness; Mutation; Myotonia Congenita; Pedigree; Sequence Deletion | 2021 |
Characterization of congenital myopathies at a Korean neuromuscular center.
Topics: Adolescent; Adult; Age of Onset; Child; Child, Preschool; Dynamin II; Dynamins; Female; Humans; Infant; Male; Muscle Fibers, Skeletal; Muscle Proteins; Mutation; Myopathies, Nemaline; Myopathies, Structural, Congenital; Myopathy, Central Core; Myotonia Congenita; Republic of Korea; Retrospective Studies; Ryanodine Receptor Calcium Release Channel; Treatment Outcome; Young Adult | 2018 |